Saturday 17 October 2026
Export SPRO’s income statement to Excel — free account
Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
1.10
0.03
−2.65%
Follow SPRO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 5 | 6 | — |
| (95.29%) | 16.31% | 35.12% | 19.17% | ||
| (46.31%) | 9.55% | 22.28% | 12.85% | ||
ROIC |
0.00% | 21.04% | 0.00% | 0.00% | |
Return on Tangible Assets |
(113.35%) | 14.67% | 29.23% | 17.11% | |
Average Days of Receivables |
22.13 | 138.71 | 0.26 | 0.00 | |
Free Cash Flow per Share |
(0.49) | (0.23) | 0.13 | 0.34 | |
Free Cash Flow |
(27.67) | (12.62) | 7.24 | 19.58 | |
| Other line items | |||||
Cash ROIC |
(36.84%) | (12.71%) | 6.64% | 20.62% | |
Accounts Receivable Turnover |
1.45 | 1.72 | 5.03 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
152.19% | 57.58% | 45.39% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
59.02% | 31.70% | 31.44% | 0.00% | |
Share Based Compensation of Revenue |
11.89% | 6.47% | 6.35% | 0.00% | |
Operating CF/Net income |
0.63 | (1.47) | 0.48 | 2.65 | |
Revenue per Share |
0.72 | 1.19 | 1.07 | 0.00 | |
Operating CF per Share |
(0.49) | (0.23) | 0.13 | 0.34 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates